Möchten Sie immer auf dem neuesten Stand bleiben?

Sangamo Therapeutics reports first quarter 2026 business updates and financial results

Austin, TX, USA, May 14, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Transgenic Animals Market Size, Trends and Insights By Type (Mice, Rats, Rabbits,...

Presented improved editing data in non-human primates (NHP) for sickle cell disease (SCD), demonstrating a single dose of Gene Writer achieved an average of 85% of long-term hematopoietic stem cells...

Prenetics records Q1 2026 revenue of $36.0 million with IM8 revenue of $33.8 million, up 23.1% from IM8 revenue of $27.4 million in Q4 2025Raises full-year 2026 IM8 revenue guidance to $190 million to...

New York, USA, May 13, 2026 (GLOBE NEWSWIRE) -- Global AI in Life Sciences Market Gearing Up for Outstanding Expansion at a CAGR of ~20% by 2034 | DelveInsight The AI in life sciences market is...

AUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: For decades, reliably identifying drug and alcohol impairment has been a persistent problem across industries, from...

CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...

– First-ever FDA approved PROTAC supports the further development and potential of Arvinas’ pipeline – – Announced FDA Approval of VEPPANU™ (vepdegestrant) for the treatment of ESR1m, ER+/HER2-...

Addition Therapeutics presents preclinical proof-of-concept data at American Society of Gene & Cell Therapy (ASGCT) 29th Annual Meeting in Boston.

Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results